Patents Assigned to KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL
-
Patent number: 11872228Abstract: The present disclosure is a pharmaceutical composition for the prevention or treatment of sepsis containing a thiamine derivative or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of the present disclosure can be used for the prevention, alleviation, or treatment of sepsis by containing fursultiamine or allithiamine to inhibit the expressions of CD40, CD86, and TNF?.Type: GrantFiled: December 21, 2021Date of Patent: January 16, 2024Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: In Kyu Lee, Eun Jung Choi, Chang Hyun Jeon, Tae-Hwan Kwon, Dong Ho Park
-
Patent number: 11597125Abstract: Disclosed is a dip-coating method as a method of coating an outer surface of a target mold including steps of: preparing and putting a supporting liquid in a container; applying a coating material to the target mold; dipping the target mold in the supporting liquid; shaking the target mold surrounded by the coating material in the supporting liquid; curing the coating material surrounding the target mold in the supporting liquid; and taking out the coated target mold from the supporting liquid.Type: GrantFiled: April 29, 2020Date of Patent: March 7, 2023Assignees: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Joonwon Kim, Seong Hyeon Kim, Dong-Hun Kang, Jaechan Park, Jongkyeong Lim, A-Reum Kim
-
Patent number: 11285226Abstract: The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR?) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.Type: GrantFiled: November 7, 2019Date of Patent: March 29, 2022Assignees: Daegu-Gyeongbuk Medical Innovation Foundation, KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, Kyungpook National University Industry-Academic Cooperation FoundationInventors: Sung Yeoun Hwang, Sung Jin Cho, Jina Kim, Jungwook Chin, Hayoung Hwang, In-Kyu Lee, Yong-Hyun Jeon, Jaetae Lee, Jae-Han Jeon, Sang Wook Kim
-
Patent number: 10934303Abstract: The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR?) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.Type: GrantFiled: September 13, 2016Date of Patent: March 2, 2021Assignees: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Sung Yeoun Hwang, Sung Jin Cho, Jina Kim, Jungwook Chin, Hayoung Hwang, In-Kyu Lee, Yong-Hyun Jeon, Jaetae Lee, Jae-Han Jeon, Sang Wook Kim
-
Patent number: 9993250Abstract: The present invention relates to a device for protecting rectal anastomosis. The device of the present invention is a double type leakage prevention system composed of micro-villi of a head filter and a triple lumen catheter, and thus minimizes contamination of the anastomotic area from intestinal contents, thereby enabling successful healing of the rectal anastomotic area. The device of the present invention has a main tube with side holes, and thus the intestinal contents, even when passing through the head filter, are sucked into the main tube through the side holes, so that the intestinal contents can be effectively drained while being diverted from the anastomotic area. The device of the present invention is inserted through the anus after surgery and thus involves less risk of additional complications due to the installation of the device, and has advantages of low manufacturing costs due to the simplification of the structure and convenient use and handling.Type: GrantFiled: December 18, 2014Date of Patent: June 12, 2018Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Jun Seok Park, Gyu Seog Choi
-
Patent number: 9468641Abstract: Disclosed herein is an anti-inflammatory pharmaceutical composition comprising a benzopyranyl tetracycle compound represented by Chemical Formula 1 as an active ingredient. The compound exhibits excellent anti-inflammatory activity by perturbing the post-translational modification of the inflammation mediator HMGB, and thus finds applications in pharmaceutical compositions superior in the treatment or prevention of inflammation-related diseases.Type: GrantFiled: April 16, 2015Date of Patent: October 18, 2016Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Seung Bum Park, Sanghee Lee, Ja Young Koo, Donghyun Lim, Jongmin Park, Kyoungho Suk, Youngpyo Nam
-
Publication number: 20160038489Abstract: Disclosed herein is an anti-inflammatory pharmaceutical composition comprising a benzopyranyl tetracycle compound represented by Chemical Formula 1 as an active ingredient. The compound exhibits excellent anti-inflammatory activity by perturbing the post-translational modification of the inflammation mediator HMGB, and thus finds applications in pharmaceutical compositions superior in the treatment or prevention of inflammation-related diseases.Type: ApplicationFiled: April 16, 2015Publication date: February 11, 2016Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Seung Bum Park, Sanghee Lee, Ja Young Koo, Donghyun Lim, Jongmin Park, Kyoungho Suk, Youngpyo Nam
-
Publication number: 20140050705Abstract: The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions.Type: ApplicationFiled: February 25, 2011Publication date: February 20, 2014Applicant: KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Jeong Ok Lim, Tae Gyun Kwon, So Young Chun, James J. Yoo
-
Publication number: 20130267008Abstract: Provided are to a freezing medium composition for cryopreserving amniotic fluid-derived stem cells, which has A lower concentration of Me2SO and eliminates fetal bovine serum and at the same time does not induce cryoinjury to fluid-derived stem cells and makes it possible to cryopreserve fluid-derived stem cells for a prolonged time using trehalose, sucrose and catalase, and a method for cryopreserving the same. According to the present invention, AFSCs can be cryopreserved with 1/4 the standard Me2SO concentration with the addition of disaccharides, antioxidants and caspase inhibitors. As a result, the use of Me2SO at low concentrations in cell freezing solutions may support the development of clinical trials of AFSCs.Type: ApplicationFiled: January 14, 2011Publication date: October 10, 2013Applicant: KYUNGPOOK NATIONAL UNIVERSITY HOSPITALInventors: Yun-Hee Shon, James J. Yoo, Jang-Soo Suh